Laurence Edward Burgess

This inventor holds 45 USPTO granted patents and 7 published patent applications, plus 4 CIPO patents and 14 EPO patents, primarily in Cancer Treatment. Top assignees: Array Biopharma Inc., Icos Corporation, Ventirx Pharmaceuticals, Inc.. Active years: 1997-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Laurence Edward Burgess. Retrieved from https://idiyas.com/inventor/laurence-edward-burgess

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 45 (Patent Applications = 7)

% Patents Active = 48.9

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 14 (Patent Applications = 12)

Average Co-Inventor Count = 5.8

ph-index = 10

Forward Citations = 367(Granted Patents)

Location History:

Gales Ferry, CT (US) (1997)
Boulder, CO (US) (1999 - 2022)

Company Filing History:

Ventirx Pharmaceuticals, Inc.

patents

4. 4 out of 44

Mirati Therapeutics, Inc.

Takeda Pharmaceutical Company Limited

Luitpold Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 1997-2022

Loading Chart...

Areas of Expertise:

KRAS Inhibitors

Janus Kinase Inhibitors

Toll-Like Receptor Modulators

Phosphodiesterase Inhibitors

Dipeptidyl Peptidase Inhibitors

Chk1 Inhibitors

Xanthones

Thioxanthones

Immunoregulatory Disorders

Cancer Agents

Phenoxychroman Derivatives

Pyrazine Compounds

45 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11267812 - KRAS G12C inhibitors (2022-03-08),

2. 11028093 - 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors (2021-06-08),

3. 10730880 - 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors (2020-08-04),

4. 10689377 - KRas G12C inhibitors (2020-06-23),

5. 10633381 - KRas G12C inhibitors (2020-04-28),

6. 10189845 - 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors (2019-01-29),

7. 10125134 - KRas G12C inhibitors (2018-11-13),

8. 9718796 - Substituted benzoazepines as toll-like receptor modulators (2017-08-01),

9. 9655904 - Substituted benzoazepines as toll-like receptor modulators (2017-05-23),

10. 9556139 - 6-substituted phenoxychroman carboxylic acid derivatives (2017-01-31),

11. 9242964 - Substituted benzoazepines as toll-like receptor modulators (2016-01-26),

12. 9126940 - Substituted benzoazepines as toll-like receptor modulators (2015-09-08),

13. 9096567 - 6-substituted phenoxychroman carboxylic acid derivatives (2015-08-04),

14. 8962596 - 5,7-substituted-imidazo[1,2-C]pyrimidines as inhibitors of JAK kinases (2015-02-24),

15. 8785445 - 7-phenoxychroman carboxylic acid derivatives (2014-07-22),

Title: **Laurence Edward Burgess: Innovator in Biomedical Inventions**

Introduction: Laurence Edward Burgess, based in Boulder, CO, is a prolific inventor known for his contributions to biomedical research, holding an impressive total of 45 patents. His work primarily focuses on developing innovative compounds that address critical health challenges.

Latest Patents: Among his latest patents, Burgess has made significant strides with the invention of KRAS G12C inhibitors. This invention relates to compounds specifically designed to irreversibly inhibit the activity of KRas G12C, along with pharmaceutical compositions that incorporate these compounds and methods of their use. Additionally, he has developed 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors. These compounds are aimed at inhibiting one or more JAK kinases and are poised to be beneficial for treating various JAK kinase-associated diseases, including autoimmune and inflammatory diseases, along with complications arising from organ transplants and hematologic disorders.

Career Highlights: Laurence Burgess has had a rich career in the biopharmaceutical sector, contributing invaluable insights and innovations. He has worked with renowned companies such as Array Biopharma Inc. and Icos Corporation, where his expertise has greatly advanced the field of drug development.

Collaborations: Throughout his career, Burgess has collaborated with notable professionals including John Joseph Gaudino and Edward A Kesicki. These collaborations have fostered a dynamic exchange of ideas and have contributed significantly to the advancement of research and development in the healthcare domain.

Conclusion: Laurence Edward Burgess exemplifies the spirit of innovation in biomedicine. His extensive portfolio of patents demonstrates his commitment to solving pressing medical challenges through creative and scientific ingenuity. As he continues to innovate, his contributions are sure to have a lasting impact on the pharmaceutical landscape.

Profile summary based on public USPTO records.